A Placebo Cannot Be Psychedelic: Why psychedelic trials need dose, not mimicry, as their control

In a recently published Viewpoint, Yang-et-al propose masking high-dose psilocybin trials with a multidrug comparator engineered to reproduce the psychedelic experience. Their objective, restoration of the gold-standard of randomized, double-blind, placebo-controlled standard, is well-intentioned, but the proposed approach dissolves the concept it aims to rescue. A placebo permits to understand the impact of expectation because it is inert. Recent neural circuit-level results in mice shows how concretely expectation affects behavior, relying on in-vivo experimentation that separates placebo effect from active treatment. A comparator that recreates the psychedelic experience must engage the circuits that generate it, becoming a second active treatment whose own pharmacology confounds any eventual difference placebo-active, possibly in both directions. Some interventions, from topical TRP-channel activators (capsaicin, menthol) to classic psychedelics, cannot be matched by an inert control. Dose-controlled designs represent the remaining option where well-intentioned mimicry fails: their main possible bias might work against the drug. Dose-controlled designs can be paired with external controls and approval tied to mandatory postmarketing evidence.